NASDAQ · TRDA
Entrada Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TRDA: Nov 5, 2026
Entrada Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.98. The reported EPS for the same quarter last year was $-1.06.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.98 | $-0.62 | $-1.18 | 4 |
| Dec 2026 | $-1.01 | $-0.92 | $-1.15 | 4 |
| Mar 2027 | $-0.95 | $-0.79 | $-1.18 | 3 |
| Jun 2027 | $-0.85 | $-0.61 | $-1.22 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · BNK Invest · Zacks · MarketBeat- RTTNews · Oct 16, 10:55 AM EDTWeekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data(RTTNews) – This week's healthcare roundup brings a series of regulatory wins, corporate restructuring, billion-dollar deals and clinical milestones.
- BNK Invest · Oct 15, 3:45 PM EDTNoteworthy Thursday Option Activity: TRDA, JBS, MCRIAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Entrada Therapeutics Inc (Symbol: TRDA), where a total of 5,011 contracts have traded so far, representing approximately 501,100 underlying shares. That amounts to about
- RTTNews · Oct 14, 9:08 AM EDTEntrada Therapeutics Advances Duchenne Study To Highest Planned Dose Level(RTTNews) – A favorable safety review has cleared the way for Entrada Therapeutics to begin testing its Duchenne muscular dystrophy candidate at the highest planned dose level in an ongoing early-stage clinical study.
- RTTNews · Oct 14, 7:30 AM EDTEntrada Reports Positive Topline Data From Cohort 1 Of Phase 1/2 ELEVATE-45-201 Study Of ENTR-601-45(RTTNews) – Entrada Therapeutics (TRDA) announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45 in ambulatory participants with a confirmed mutation in th
- RTTNews · Aug 7, 1:03 AM EDTEntrada Q2 Loss Shrinks; Data From Phase 1/2 Trials In DMD And DM1 Expected In '27(RTTNews) – Entrada Therapeutics, Inc. (TRDA) recorded a narrower loss for the second quarter ended June 30, 2026, and highlighted various clinical updates.
- Zacks · Aug 5, 9:00 AM EDTEntrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue EstimatesEntrada Therapeutics (TRDA) delivered earnings and revenue surprises of +12.93% and +2.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 3, 8:05 AM EDTCompugen (CGEN) Reports Q2 Loss, Misses Revenue EstimatesCompugen (CGEN) delivered earnings and revenue surprises of 0.00% and -3.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 30, 9:35 AM EDTWave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue EstimatesWave Life Sciences (WVE) delivered earnings and revenue surprises of -9.68% and -73.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- MarketBeat · May 9, 2:07 AM EDTEntrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety ProfileVertex Pharmaceuticals Hits Record High on Strong Q1 EarningsEntrada Therapeutics (NASDAQ:TRDA) said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable safety and tolerability and early functional improvement in ambulatory patients with Duc
- Zacks · May 7, 8:50 AM EDTEntrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue EstimatesEntrada Therapeutics (TRDA) delivered earnings and revenue surprises of +10.59% and -86.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 5, 9:12 AM EDTEntrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Zacks · May 4, 5:10 PM EDTTravere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue EstimatesTravere (TVTX) delivered earnings and revenue surprises of -30.74% and -1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Entrada Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.